You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Recombinant E-NTPDase for shock
SBC: Purine Pharmaceuticals Inc. Topic: 300SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NHLBISummary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters
SBC: NYTRICX INC Topic: NHLBIAbstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis
SBC: Prokaryotics, Inc. Topic: NIAIDWidespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Next-generation nanomedicine for acute ischemic stroke
SBC: Nanomuse, LLC Topic: NINDSABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.
SBC: Zena Therapeutics Inc. Topic: NIDAOpioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups
SBC: JP LABORATORIES INC Topic: 300Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease
SBC: VASADE BIOSCIENCES, INC. Topic: NIAProject Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Disseminable Evidence-Based Treatment for the Dental Office: Virtual Exposure Tools for Dental Fear- neVR Fear the Dentist
SBC: VIRTUALLY BETTER INC Topic: NIDCRPROJECT SUMMARY/ABSTRACTEach year over 20 million adults with moderate fear and over 14 million adults with severe fear visit the dentist. Because fear portends poor future oral health, patients with dental fear come to experience their worst fears: pain, surgical procedures, and the need for more frequent dental visits. Avoidance is the natural and reinforced response, ironically guaranteeing a r ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Simulated Exposure Trainer (SET-VR): Implementing Targeted Experiential Training with a Virtual Patient
SBC: VIRTUALLY BETTER INC Topic: 104PROJECT SUMMARY/ABSTRACT Despite the existence of numerous, well-established evidence-based practices (EBPs) for mental disorders, it has been difficult to disseminate these practices in community settings. Exposure therapy for anxiety disorders represents one of the most glaring examples of this research-to-practice gap. Just as patients are anxious about approaching their fears, therapists are o ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health